What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve patient outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve patient outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with targeted therapy, in breast, long (NSLC), and colorectal cancer?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Jianming Xu, MD

Professor Jianming Xu, MD

Affiliated Hospital Cancer Center
Academy of Military Medical Sciences
Beijing, China